Terbinafine in the treatment of onychomycosis: A review of its efficacy in high-risk populations and in patients with nondermatophyte infections

British Journal of Dermatology

Volumn 150, Issue 3, 2004, Pages 414-420

  Cribier, B J ^a   Bakshi, R ^b  

^a UNIVERSITY HOSPITAL OF STRASBOURG   (France)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Diabetes; Human immunodeficiency virus; Immunocompromise; Nondermatophyte; Onychomycosis; Terbinafine

Indexed keywords

ANTIRETROVIRUS AGENT; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; TERBINAFINE;

BLOOD DISEASE; CALCULATION; CANDIDA; DERMATOMYCOSIS; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; GRAFT REJECTION; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; IMMUNOCOMPETENCE; IMMUNOSUPPRESSIVE TREATMENT; INTERNATIONAL COOPERATION; KIDNEY DISEASE; KIDNEY FUNCTION; LIVER DISEASE; MEDLINE; NAIL INFECTION; ONYCHOMYCOSIS; PREVALENCE; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

ANTIFUNGAL AGENTS; CANDIDIASIS, CUTANEOUS; DIABETES COMPLICATIONS; HIV INFECTIONS; HUMANS; IMMUNOSUPPRESSION; KIDNEY TRANSPLANTATION; NAPHTHALENES; ONYCHOMYCOSIS; TREATMENT OUTCOME;

EID: 1842611088     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2133.2003.05726.x     Document Type: Review

References (40)

1. Levy A. Epidemiology of onychomycosis in special-risk populations. J Am Podiatr Med Assoc 1997; 87: 546-50.
2. Heikkilä H, Stubb S. The prevalence of onychomycosis in Finland. Br J Dermatol 1995; 133: 699-703.
3. Dogra S, Kumar B, Bhansali A, Chakrabarty A. Epidemiology of onychomycosis in patients with diabetes mellitus in India. Int J Dermatol 2002; 41: 647-51.
4. Gupta AK, Konnikov N, MacDonald P et al. Prevalence and epidemiology of toenail onychomycosis in diabetic subjects: a multicentre study. Br J Dermatol 1998; 138: 665-71.
5. Cribier BJ, Leiva Mena M, Rey D et al. Nail changes in patients infected with human immunodeficiency virus. A prospective controlled study. Arch Dermatol 1998; 134: 1216-20.
6. Virgili A, Zampino MR, La Malfa V et al. Prevalence of superficial dermatomycoses in 73 renal transplant recipients. Dermatology 1999; 199: 31-4.
7. Sentamil Selvi G, Kalamam A, Ajithados K et al. Clinical and mycological features of dermatophytosis in renal transplant recipients. Mycoses 1999; 42: 75-8.
8. Korting HC, Schäfer-Korting M. Is tinea unguium still widely incurable? A review three decades after the introduction of griseofulvin. Arch Dermatol 1992; 128: 243-8.
9. Evans EGV, Sigurgeirsson B for the LION Study Group. Double-blind, randomised study of continuous terbinafine compared with intermittent itraconazole in the treatment of toenail onychomycosis. Br Med J 1999; 318: 1031-5.
10. Cribier BJ, Paul C. Long-term efficacy of antifungals in toenail onychomycosis: a critical review. Br J Dermatol 2001; 145: 446-52.
11. Sigurgeirsson B, Olafsson JH, Steinsson JP et al. Long-term effectiveness of treatment with terbinafine vs itraconazole in onychomycosis. A 5-year blinded prospective follow-up study. Arch Dermatol 2002; 138: 353-7.
12. Bradley MC, Leidich S, Isham N et al. Antifungal susceptibilities and genetic relatedness of serial Trichophyton rubrum isolates from patients with onychomycosis of the toenail. Mycoses 1999; 42 (Suppl. 2): 105-10.
13. Elewski BE. Large-scale epidemiological study of the causal agents of onychomycosis: mycological findings from the Multicenter Onychomycosis Study of Terbinafme. Arch Dermatol 1997; 133: 1317-18.
14. Evans EG. Causative agents in onychomycosis and the possibility of treatment resistance: a review. J Am Acad Dermatol 1998; 38: S32-6.
15. Rich F, Karchmer A, Atillasoy ES. The safety and efficacy of oral terbinafine in the treatment of onychomycosis in diabetic patients. J Eur Acad Dermatol Venereal 1999; 12 (Suppl. 2): S229.
16. Bohannon NJ, Streja L. Effectiveness of terbinafine therapy for toenail onychomycosis in persons with diabetes. Diabetes 2000; 49 (Suppl. 1): A195.
17. Farkas B, Paul C, Dobozy A et al. Terbinafine (Lamisil®) treatment of toenail onychomycosis in patients with insulin-dependent and non-insulin-dependent diabetes mellitus: a multicentre trial. Br J Dermatol 2002; 146: 254-60.
18. Nandwani R, Parnell A, Youle M et al. Use of terbinafine in HIV-positive subjects: pilot studies in onychomycosis and oral candidiasis. Br J Dermatol 1996; 134 (Suppl. 46): 22-4.
19. Herranz P, Garcaia J, De Lucas R et al. Toenail onychomycosis in patients with acquired immune deficiency syndrome: treatment with terbinafine. Br J Dermatol 1997; 137: 577-80.
20. Jensen P, Lehne G, Fauchald P, Simonsen S. Effect of oral terbinafine treatment on cyclosporin pharmacokinetics in organ transplant recipients with dermatophyte nail infection. Acta Derm Venereol (Stockh) 1996; 76: 280-1.
21. Lo AC, Lui SL, Lo WK et al. The interactions of terbinafine and cyclosporine A in renal transplant patients. Br J Clin Pharmacol 1997; 43: 340-1.
22. Lee KH, Kim YS, Kim MS et al. Study of the efficacy and tolerability of oral terbinafine in the treatment of onychomycosis in renal transplant patients. Transplant Proc 1996; 28: 1488-9.
23. Ellis DH, Watson AB, Marley JE, Williams TG. Non-dermatophytes in onychomycosis of the toenails. Br J Dermatol 1997; 136: 490-3.
24. Ellis DH, Marley JE, Watson AB, Williams TG. Significance of non-dermatophyte moulds and yeasts in onychomycosis. Dermatology 1997; 194 (Suppl. 1): 40-2.
25. Watson AB, Marley JE, Ellis DH, Williams TG. Terbinafine in onychomycosis of the toe-nail: a novel treatment protocol. J Am Acad Dermatol 1995; 33: 775-9.
26. Lebwohl MG, Daniel CR, Leyden J et al. Efficacy and safety of terbinafine for nondermatophyte and mixed nondermatophyte and dermatophyte toenail onychomycosis. Int J Dermatol 2001; 40: 358-60.
27. Nolting S, Brautigam M, Weidinger G. Terbinafine in onychomycosis with involvement by non-dermatophyte fungi. Br J Dermatol 1994; 130 (Suppl. 43): 16-21.
28. Segal R, Kritzman A, Cividalli L et al. Treatment of Candida nail infection with terbinafine. J Am Acad Dermatol 1996; 35: 958-61.
29. Zaidi Z, Jafri N, Hasan P, Kapadia N. Open label trial of the efficacy and tolerability of Lamisil (terbinafine) 500 mg once daily in the treatment of onychomycosis due to Candida. J Pak Med Assoc 1996; 46: 258-60.
30. Tosti A, Piraccini BM, Stinchi C, Lorenzi S. Onychomycosis due to Scopulariopsis brevicaulis: clinical features and response to systemic antifungals. Br J Dermatol 1996; 135: 799-802.
31. Gupta AK, Gregurek-Novak T, Konnikov N et al. Itraconazole and terbinafine treatment of some nondermatophyte molds causing onychomycosis of the toes and a review of the literature. J Cutan Med Surg 2001; 5: 206-10.
32. Gupta AK, Gregurek-Novak T. Efficacy of itraconazole, terbinafine, fluconazole, griseofulvin and keratoconazole in the treatment of Scopulariopsis brevicaulis causing onychomycosis of the toes. Dermatology 2001; 202: 235-8.
33. Tosti A, Piraccini BM, Lorenzi S. Onychomycosis caused by non dermatophyte molds: clinical features and response to treatment of 59 cases. J Am Acad Dermatol 2000; 42: 217-24.
34. Gianni C, Cerri A, Crosti C. Unusual clinical features of fingernail infection by Fusarium oxysporum. Mycoses 1997; 40: 455-9.
35. Haugh M, Helou S, Boissel JP, Cribier BJ. Terbinafine in fungal infections of the nails: a meta-analysis of randomized clinical trials. Br J Dermatol 2002; 147: 118-21.
36. Gupta AK, Humke S. The prevalence and management of onychomycosis in diabetic patients. Eur J Dermatol 2000; 10: 379-84.
37. Pollak R, Bilstein SA. Safety of oral terbinafine for toenail onychomycosis. J Am Podiatr Med Assoc 1997; 87: 56-70.
38. Novartis Pharma AG. Lamisil Prescribing Information. http:// www.pharma.ca.novartis.com
39. Brinbaum JF. Pharmacology of allylamines. J Am Acad Dermatol 1990; 23: 782-5.
40. Balfour JA, Fauds D. Terbinafine. A review on its pharmacodynamic and pharmacokinetic properties and therapeutic potential in superficial mycoses. Drugs 1992; 43: 259-84.